Preclinical pharmacokinetics of paclitaxel and docetaxel

Alex Sparreboom(The Ohio State University), Jos H. Beijnen(The Netherlands Cancer Institute), Olaf van Tellingen(Dutch Cancer Society), Willem J. Nooijen(The Netherlands Cancer Institute)
Anti-Cancer Drugs
January 1, 1998
10.1097/00001813-199801000-00001
Cited by 148

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884